Celcuity To Participate in Upcoming Investor Conferences

Rhea-AI Summary

Celcuity (Nasdaq: CELC) announced CEO Brian Sullivan will present and hold one-on-one investor meetings at two upcoming healthcare investor conferences in June 2026.

Both fireside chats at Jefferies and Goldman Sachs will be available via live webcast and replay through dedicated links and the company’s investor relations website.

News Market Reaction – CELC

-2.28%

2 alerts

-2.28% Session close to close

$6.25B Market Cap

0.0x Rel. Volume

In the May 28 session, CELC declined 2.28%, reflecting a moderate negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MINNEAPOLIS, May 28, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications, today announced that Brian Sullivan, Chief Executive Officer and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences:

• A fireside chat at the Jefferies Global Healthcare Conference at 1:25 p.m. EDT on Thursday, June 4, 2026. A live webcast will be available using this weblink: https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/CMgAqyC4qKWHVGdLtG2QB8
• A fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference 2026 at 8:00 a.m. EDT on Wednesday, June 10, 2026. A live webcast will be available using this weblink: https://event.webcasts.com/viewer/event.jsp?ei=1765258&tp_key=8bf99aba87

Alternatively, the live webcasts will be accessible from the Investors section of the company's website at https://ir.celcuity.com/events-presentations/ with a replay available shortly after the live events.

About Celcuity

Celcuity is a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications. Our lead therapeutic candidate is gedatolisib, a kinase inhibitor of the PI3K/AKT/mTOR (“PAM”) pathway that binds to all class I PI3K isoforms and the mTOR complexes, mTORC1 and mTORC2. By targeting all class I PI3K isoforms and mTORC1/2, gedatolisib induces comprehensive inhibition of the PAM pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT, or mTORC1 alone or together. Our Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) (“HR+/HER2-”) locally advanced or metastatic breast cancer (“ABC”), has reported detailed results for Study 1, which evaluated patients with PIK3CA wild-type (“WT”) tumors, and announced topline results for Study 2, which evaluated patients with PIK3CA mutant-type (“MT”) tumors. Our Phase 3 clinical trial, VIKTORIA-2, is ongoing and incorporates two independent studies, Study 1 and Study 2, evaluating two separate cohorts of patients with ABC who are treatment-naive in the advanced setting. Study 1 is evaluating gedatolisib combined with palbociclib and fulvestrant as first-line treatment for patients with endocrine-resistant HR+/HER2- ABC. Study 2 is evaluating gedatolisib combined with palbociclib and letrozole as first-line treatment for patients with endocrine-sensitive HR+/HER2- ABC. A Phase 1b/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is ongoing. More detailed information about Celcuity’s active clinical trials can be found at ClinicalTrials.gov. Celcuity is headquartered in Minneapolis, Minnesota. Further information about Celcuity can be found at www.celcuity.com. Follow us on LinkedIn and X.

Contacts: 

Celcuity Inc. 
Brian Sullivan, bsullivan@celcuity.com
Vicky Hahne, vhahne@celcuity.com  
(763) 392-0123  
Jodi Sievers, jsievers@celcuity.com
(415) 494-9924

FAQ

When will Celcuity (CELC) present at the Jefferies Global Healthcare Conference 2026?

Celcuity will present at the Jefferies Global Healthcare Conference on Thursday, June 4, 2026, at 1:25 p.m. EDT. According to Celcuity, CEO Brian Sullivan will host a fireside chat and be available for one-on-one investor meetings.

How can investors watch Celcuity's Jefferies Global Healthcare Conference 2026 webcast?

Investors can watch Celcuity’s Jefferies fireside chat via a dedicated live webcast link. According to Celcuity, the webcast is also accessible through the Investors section of its website, with a replay available shortly after the live event.

What are the date and time for Celcuity's Goldman Sachs Global Healthcare Conference 2026 presentation?

Celcuity presents at the Goldman Sachs 47th Annual Global Healthcare Conference on Wednesday, June 10, 2026, at 8:00 a.m. EDT. According to Celcuity, Brian Sullivan will participate in a fireside chat and investor meetings.

Where can investors access Celcuity (CELC) conference webcasts and replays?

Investors can access Celcuity’s conference webcasts via the specific event links and its investor relations website. According to Celcuity, replays for both Jefferies and Goldman Sachs fireside chats will be available shortly after the live webcasts.

Will Celcuity management be available for one-on-one investor meetings at June 2026 conferences?

Yes, CEO Brian Sullivan will be available for one-on-one investor meetings at both June 2026 conferences. According to Celcuity, these meetings will coincide with the Jefferies and Goldman Sachs fireside chat presentations.